Literature DB >> 17364192

Illusions of objectivity and a recommendation for reporting data mining results.

Manfred Hauben1, Lester Reich, Charles M Gerrits, Muhammad Younus.   

Abstract

OBJECTIVE: Data mining algorithms (DMAs) are being applied to spontaneous reporting system (SRS) databases in the hope of obtaining timely insights into post-licensure safety data. Some DMAs have been characterized as "objective" screening tools. However, there are numerous available modifiable configuration parameters to choose from, including choice of vendor, that may affect results. Our objective is to compare the data mining results on pre-selected drug-event combinations (DECs) between two commonly used software programs using similar protocols.
METHODS: Two DMAs, using three thresholds, were retrospectively applied to the USFDA safety database through Q2 2005 to a set of eight pre-selected DECs.
RESULTS: Differences between the two vendors were found for the number of cases associated with a signal of disproportionate reporting (SDR), first year of SDRs, and the magnitude of the SDR scores for the selected DECs. These were deemed to be potentially significant for 45.8% (11/24) of the data points.
CONCLUSION: The observed differences between vendors could partially be explained by their differing methods of data cleaning and transformation as well as by the specific features of individual algorithms. The choices of vendors and available data mining configurations maximize the exploratory capacity of data mining, but they also raise questions about the claimed objectivity of data mining results and can make data mining exercises susceptible to confirmation bias given the exploratory nature of data mining in pharmacovigilance. When reporting results, the vendor and all data mining configuration details should be specified.

Entities:  

Mesh:

Year:  2007        PMID: 17364192     DOI: 10.1007/s00228-007-0279-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

2.  Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.

Authors:  Ana Szarfman; Stella G Machado; Robert T O'Neill
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Data mining, drug safety, and molecular pharmacology: potential for collaboration.

Authors:  Manfred Hauben; Lester Reich
Journal:  Ann Pharmacother       Date:  2004-11-09       Impact factor: 3.154

4.  Data mining in pharmacovigilance: the need for a balanced perspective.

Authors:  Manfred Hauben; Vaishali Patadia; Charles Gerrits; Louisa Walsh; Lester Reich
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance.

Authors:  Emmanuel Roux; Frantz Thiessard; Annie Fourrier; Bernard Bégaud; Pascale Tubert-Bitter
Journal:  IEEE Trans Inf Technol Biomed       Date:  2005-12

Review 6.  Data mining in spontaneous reports.

Authors:  Andrew Bate; I R Edwards
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-03       Impact factor: 4.080

7.  Data mining in pharmacovigilance: lessons from phantom ships.

Authors:  Manfred Hauben; Lester Reich; Eugène P Van Puijenbroek; Charles M Gerrits; Vaishali K Patadia
Journal:  Eur J Clin Pharmacol       Date:  2006-08-03       Impact factor: 2.953

8.  What counts in data mining?

Authors:  Manfred Hauben; Vaishali K Patadia; David Goldsmith
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

9.  Extension of points on clarifying terminology in drug safety.

Authors:  Manfred Hauben; Lester Reich; Flic Gabbay
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 10.  Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects.

Authors:  Richard Solomon; William Dumouchel
Journal:  Invest Radiol       Date:  2006-08       Impact factor: 6.016

View more
  7 in total

1.  Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods.

Authors:  Jessica A Reese; Xiaoning Li; Manfred Hauben; Richard H Aster; Daniel W Bougie; Brian R Curtis; James N George; Sara K Vesely
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

2.  A decade of data mining and still counting.

Authors:  Manfred Hauben; G Niklas Norén
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

3.  Intelligent risk communication: can it be improved?

Authors:  Andrzej Czarnecki
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.

Authors:  Steven Bailey; Ajay Singh; Robert Azadian; Peter Huber; Michael Blum
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

5.  Revisiting the reported signal of acute pancreatitis with rasburicase: an object lesson in pharmacovigilance.

Authors:  Manfred Hauben; Eric Y Hung
Journal:  Ther Adv Drug Saf       Date:  2016-05-23

6.  Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database.

Authors:  Manfred Hauben; Eric Y Hung; Kelly C Hanretta; Sripal Bangalore; Vincenza Snow
Journal:  Drug Saf       Date:  2015-11       Impact factor: 5.606

7.  Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.

Authors:  Kaori Nomura; Kunihiko Takahashi; Yasushi Hinomura; Genta Kawaguchi; Yasuyuki Matsushita; Hiroko Marui; Tatsuhiko Anzai; Masayuki Hashiguchi; Mayumi Mochizuki
Journal:  Drug Des Devel Ther       Date:  2015-06-12       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.